Macrogen said it has completed the expansion and relocation of its branch in Spain, with the aim of strengthening its competitiveness in the European market.
It is part of Macrogen’s strategy to build a global network of genome centers. The company opened a new genome center in Maastricht, the Netherlands, in August.
“The new Spanish branch is in the center of Madrid and has high access to medical facilities such as large teaching hospitals, general hospitals and examination centers,” a company official told Korea Biomedical Review on Thursday. “The company plans to promote the expansion of clinical diagnostics and treatment services business through the outsourced branch.”
The old branch was on the outskirts of Madrid, she added.
With the relocation, the company plans to advance in the European clinical diagnostics and treatment market based on the business and technological capabilities accumulated in the local genome analysis market. The Macrogen Spain branch maintains a leading position in the Spanish next-generation sequencing market with over 40% market share in the third quarter and expands its business by attracting customers to Portugal.
The Spanish branch will also provide a fast and accurate Covid-19 diagnostic service. He is working on signing a business agreement with a local travel agency so Korean tourists visiting Spain can take Covid-19 tests without language or cultural difficulties.
“As the world shifts to the ‘live with Covid’ diet, the Covid-19 diagnostic test will become common in everyday life,” said Cha Seung-heon, manager of the Spanish branch. “We expect that, thanks to Macrogen’s new Covid-19 diagnostic service, Spaniards, foreigners and tourists will receive Covid-19 test results easier and faster. “
Macrogen will also open a new genome center in Milan, Italy next year, taking another step towards building the global network.
“The opening of the new center is a key milestone in providing personalized services to major base countries, which is good news for customers across Europe and Africa,” said Kim Bong-cho. , CEO of Macrogen Europe. “Macrogen Europe plans to continue to expand its network of genome centers to provide the fastest and most reliable service.”